THE Department of Health and Ageing has advised that public consultation is now open around the listing of glucagon-like peptide-1 receptor agonist (GLP-1) medicines such as Ozempic and Mounjaro for the treatment of obesity.

After a request from the Minister for Health earlier this year, the Pharmaceutical Benefits Advisory Committee (PBAC) will be discussing equitable access to the drugs through the Pharmaceutical Benefits Scheme (PBS) at its Nov meeting.

In addition to considering research findings, it is currently seeking input from consumers, health professionals and other stakeholders.

Consultation is open until 24 Sep through the Consultation Hub – to contribute, click HERE.

The post PBAC consults on obesity drugs appeared first on Pharmacy Daily.